Principia Biopharma Reacquires Rights to Oral Immunoproteasome Program
-- Principia and AbbVie mutually agree to end collaboration -- -- Preclinical stage program focused on development of oral immunoproteasome inhibitors to treat inflammation and autoimmune disorders -- SOUTH SAN FRANCISCO, Calif., March 11, 2019 (GLOBE …